Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
Rare tumors constitute a substantial portion of cancer diagnoses, however, research remains limited. To assess the utility of genomic testing for informing treatment decisions, we retrospectively evaluated the landscape of actionable genomic alterations and immune biomarkers in rare tumors. Genomic and clinical data fr...
Guo-Min Lin, Yue Hao, Qian Wang et al.· International Open Medical J...· 0 citations
It is demonstrated that SMAD4 regulated 3D genome organization through its canonical transcription factor activity by directly binding chromatin, thereby suppressing lung tumorigenesis and revealing enhancer–promoter rewiring as a key mechanism driving lung tumorigenesis and a potential therapeutic vulnerability in SMA...
Ya-Ping Xu, Xin-Yan Han, Jun-Ming Li et al.· Oncogene· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.